Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs Martha Hickey, M.D., Jenny Higham, M.D., Mark Sullivan, Ph.D., Lyn Miles, Ian S Fraser Fertility and Sterility Volume 75, Issue 2, Pages 288-296 (February 2001) DOI: 10.1016/S0015-0282(00)01690-3
Figure 1 Diagram of subcloning required to produce the probes for this investigation, showing the different procedures for TIMP-1 (A) and MMP-9 (B). Hickey. Endometrial bleeding in HRT recipients. Fertil Steril 2001. Fertility and Sterility 2001 75, 288-296DOI: (10.1016/S0015-0282(00)01690-3)
Figure 2 RNA sequences used for the in situ hybridization procedures. They are complementary to the mRNA sequences and are printed in the 5′-3′ orientation. Hickey. Endometrial bleeding in HRT recipients. Fertil Steril 2001. Fertility and Sterility 2001 75, 288-296DOI: (10.1016/S0015-0282(00)01690-3)
Figure 3 In situ hybridization for MMP-9 (A) and (B) TIMP-1 in control tissues. Positive cells are indicated by arrows, demonstrating discrete staining. This would be classified as 2 in both cases (weak, localized immunostaining). Original magnification: A, ×100; B, ×200. Hickey. Endometrial bleeding in HRT recipients. Fertil Steril 2001. Fertility and Sterility 2001 75, 288-296DOI: (10.1016/S0015-0282(00)01690-3)